Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Kamada Ltd. (KMDA)

4.45   -0.07 (-1.55%) 01-27 16:00
Open: 4.5 Pre. Close: 4.52
High: 4.55 Low: 4.401
Volume: 25,253 Market Cap: 199(M)

Technical analysis

as of: 2023-01-27 4:45:51 PM
Stoxline posted a SELL today, same as yesterday. Downward movement continues.
Target: Six months: 5.54     One year: 6.28
Support: Support1: 3.72    Support2: 3.09
Resistance: Resistance1: 4.74    Resistance2: 5.38
Pivot: 4.79
Moving Average: MA(5): 4.59     MA(20): 4.64
MA(100): 4.51     MA(250): 4.9
MACD: MACD(12,26): 0     Signal(9): 0.1
Stochastic oscillator: %K(14,3): 23.6     %D(3): 34.2
RSI: RSI(14): 45.8
52-week: High: 6.17  Low: 3.72
Average Vol(K): 3-Month: 57 (K)  10-Days: 25 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ KMDA ] has closed above bottom band by 13.2%. Bollinger Bands are 27.7% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 4.56 - 4.59 4.59 - 4.61
Low: 4.32 - 4.36 4.36 - 4.39
Close: 4.39 - 4.45 4.45 - 4.49

Company Description

Kamada Ltd. provides plasma-derived protein therapeutics. It operates in two segments, Proprietary Products and Distribution. The company offers KAMRAB/KEDRAB for prophylaxis of rabies disease; CYTOGAM for prophylaxis of cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplant; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; VARIZIG for post exposure prophylaxis of varicella; and GLASSIA for intravenous AATD. It also provides KamRho (D) IM for prophylaxis of hemolytic disease of newborns; KamRho (D) IV for immune thermobocytopunic purpura; and snake bite antiserum to treat snake bites by the vipera palaestinae and echis coloratus. In addition, the company distributes BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN for Allergic rhinitis and Urticaria; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for cytomegalovirus virus; RUCONEST for angioedema attacks; heparin sodium injection for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. Further, it offers IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis ; and ELIGARD for prostate cancer. The company markets its products through strategic partners in the United States, as well as through distributors internationally. Kamada Ltd. has strategic partnerships with Takeda Pharmaceuticals Company Limited; PARI GmbH; and Kedrion Biopharma. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.

Headline News

Sun, 29 Jan 2023
In a 1st, Cabinet meet to be held in Salt Lake today - Millennium Post

Fri, 27 Jan 2023
Civic body to plant 25 lakh saplings to check pollution - The Statesman

Wed, 25 Jan 2023
Is Kamada (TLV:KMDA) Using Too Much Debt? - Simply Wall St

Wed, 25 Jan 2023
Plan to relocate settlers for repairing work of Bankim Setu in Howrah - Times of India

Fri, 20 Jan 2023
State nod to convert leasehold land to freehold - Millennium Post

Wed, 18 Jan 2023
Hakim assures demolition of illegal construction on ‘usurped KMDA lands’ - Millennium Post

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Outperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Neutral
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Drug Manufacturers—Specialty & Generic
Shares Out. 45 (M)
Shares Float 28 (M)
% Held by Insiders 18.5 (%)
% Held by Institutions 32.3 (%)
Shares Short 453 (K)
Shares Short P.Month 501 (K)

Stock Financials

EPS -0.16
EPS Est Next Qtl 0.05
EPS Est This Year 0.09
EPS Est Next Year 0.18
Book Value (p.s.) 3.93
Profit Margin (%) -8.9
Operating Margin (%) -0.9
Return on Assets (ttm) -0.3
Return on Equity (ttm) -5.9
Qtrly Rev. Growth 39.9
Gross Profit (p.s.) 0.67
Sales Per Share 2.57
EBITDA (p.s.) 0.2
Qtrly Earnings Growth 0
Operating Cash Flow 17 (M)
Levered Free Cash Flow 21 (M)

Stock Valuations

PE Ratio -29.67
PEG Ratio -10.5
Price to Book value 1.13
Price to Sales 1.72
Price to Cash Flow 11.81

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0.2%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.